Scientists at the University of British Columbia have developed a groundbreaking gene-editing treatment for skin conditions, marking a significant advancement in medical science. This innovative therapy, created in collaboration with researchers from the Berlin Institute of Health at Charité in Germany, offers a potential cure for a wide range of genetic skin disorders, from rare inherited diseases to common conditions like eczema.
The research, published in the journal Cell Stem Cell, introduces a novel gene therapy that can correct faulty genes directly on human skin. Dr. Sarah Hedtrich, an associate professor at UBC's School of Biomedical Engineering and the study's senior author, explains, 'With this work, we demonstrate the feasibility of correcting disease-causing mutations in human skin using a topical treatment that is safe, scalable, and user-friendly.'
The therapy targets autosomal recessive congenital ichthyosis (ARCI), a rare and life-threatening skin disorder that causes extreme dryness, scaling, chronic inflammation, and infection risks. Current treatments are ineffective, and patients must manage symptoms indefinitely. The study's findings are promising, as the treatment restored up to 30% of normal skin function in human skin models, a level considered clinically significant.
Dr. Hedtrich emphasizes the broad therapeutic potential, stating, 'The approach we developed is a versatile platform technology. It can be adapted to treat almost any skin disease.' This includes conditions like epidermolysis bullosa, known as 'butterfly skin,' and potentially more common disorders such as eczema and psoriasis.
The key challenge in applying gene-editing technology to skin diseases is the skin's protective barrier, which hinders the delivery of large biological therapies. The research team addressed this by developing a novel delivery method using lipid nanoparticle technology (LNP). These microscopic fat bubbles, pioneered by UBC professor Dr. Pieter Cullis, have been instrumental in mRNA vaccines, enabling the transport of gene-editing technology into cells.
The process involves creating microscopic, pain-free openings in the skin's outer layers using a clinically approved laser, allowing lipid nanoparticles to reach skin stem cells beneath the surface. Once inside, the gene editor corrects the underlying DNA mutation, enabling the skin to function more normally.
Dr. Hedtrich highlights the targeted and localized nature of the treatment, emphasizing its safety and lack of off-target effects. The study was conducted in collaboration with NanoVation Therapeutics, a UBC spin-off focused on LNP-based genetic medicines. The researchers aim to initiate clinical trials and have engaged with regulatory authorities to define safety and efficacy studies.
In summary, this groundbreaking research offers a promising new approach to treating genetic skin conditions, potentially transforming the lives of patients with limited therapeutic options. The team's dedication to innovation and collaboration paves the way for future advancements in gene therapy and skin disease management.
